[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cannabis-intoxication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cannabis-intoxication":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,97,124,152,177,198,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100584583","study-of-an-oral-fluid-testing-approach-100584583",false,"NCT06891235","Study of an Oral Fluid Testing Approach","Oral Fluid Testing to Assess Cannabis Non-Use in Remote Clinical Trials","SOFTA","Inclusion Criteria:\n\n* Age 18 to 30 years\n* Cannabis use on \\>=1x\u002Fweek in the past 30 days\n* Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)\n* Ability to read and speak English\n* Availability for duration of the study (3-4 weeks).\n* To proceed to oral fluid testing, positive result for urinary TCH-COOH\n\nExclusion Criteria:\n\n• Inability\u002Funwillingness to provide contact information","ALL","18 Years","30 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \\~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).",[26,27,28],"Cannabis Use","Cannabis Intoxication","Cannabis Use Disorder",[30,31,32],"cannabis use","young adult","oral fluid testing","RECRUITING","2026-06-27",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2025-10-27",{"date":41,"type":22},"2027-05",{"name":43,"class":44},"Boston Children's Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100619125","neuroimaging-of-adolescent-cannabis-use-treatment-100619125","NCT07340554","Neuroimaging of Adolescent Cannabis Use Treatment","Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment","ACT","Inclusion Criteria:\n\n* 14-17 year old youth\n* Guardian 18 years or older\n* Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and\u002For hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant\n* Youth must endorse having used cannabis at least once per week over the past month OR youth must have been diagnosed with cannabis use disorder within the past three months\n\nExclusion Criteria:\n\n* Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent\u002Fguardian report\n* Youth or caretaker who is monolingual non-English speaker\n* Youth who is currently experiencing active psychosis symptoms or suicidal\u002Fhomicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality\u002Fhomicidality\n* Youth who is currently undergoing contingency management treatment for cannabis use disorder","14 Years","17 Years",{"count":57,"type":22},80,"INTERVENTIONAL",[60],"NA","This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.",[26,63,28,64,27,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85],"Cannabis Dependence","Cannabis Abuse","Cannabis Smoking","Cannabis Withdrawal","Cannabis-Related Disorder","Cannabis Abuse, in Remission","Cannabis Abuse, Episodic Use","Marijuana","Marijuana Abuse","Marijuana Use","Marijuana Smoking","Marijuana Dependence","Marijuana User","Marijuana-Related Disorder","Marijuana Use Disorder","Addiction","Addiction, Substance","Substance Use","Substance Use Disorders","Substance Dependence","Substance Abuse","Substance Related Problem","Substance Abuse Drug Chronic",[87,70,78],"Cannabis","2026-06-18",{"date":90,"type":37},"2026-06-22",{"date":92,"type":37},"2026-06-15",{"date":94,"type":22},"2030-05-01",{"name":96,"class":44},"Indiana University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":58,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100609405","phase-1-effects-of-various-cannabis-strains-on-perceptual-subjective-and-objective-use-outcomes-100609405","NCT07214155","Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes","Inclusion Criteria:\n\n* Have provided written informed consent.\n* Be between the ages of 21 and 55\n* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n* Test negative for drugs of abuse including breath alcohol at the screening visit and at clinic admission\n* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. Participants must confirm use of appropriate birth control methods (e.g., condoms, birth control pills) throughout the entirety of the study.\n* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg\n* Have prior experience smoking cannabis but not currently using more than 3 times per week on average; participants must be active cannabis users (i.e., report past 3-month use) to participate.\n\nExclusion Criteria:\n\n* Self-reported use of illicit drugs (e.g., amphetamine, cocaine, methamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.\n* History of or current evidence of significant medical (e.g., seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.\n* History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).\n* Enrolled in another clinical trial or having received any drug as part of a research study within 30 days prior to dosing.\n* Having previously sought medical attention to manage adverse effects following acute cannabis use\n* Individuals with anemia or who have donated blood in the prior 30 days",true,"21 Years","55 Years",{"count":107,"type":22},70,[109],"PHASE1","This study will evaluate the subjective and behavioral effects of cannabis products labeled as indica, sativa, or generic.",[27],[87,113,114],"Indica","Sativa","NOT_YET_RECRUITING","2026-05-21",{"date":118,"type":37},"2026-05-22",{"date":92,"type":22},{"date":121,"type":22},"2029-09",{"name":123,"class":44},"Johns Hopkins University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":103,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":58,"phases":133,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":45},"100609600","phase-2-pregnenolone-as-a-treatment-for-cannabis-intoxication-100609600","NCT07216690","Pregnenolone as a Treatment for Cannabis Intoxication","Inclusion Criteria\n\n* Ages 18-65\n* Good general health based on screening procedures (e.g. physical exam, blood testing, psychiatric evaluation)\n* Systolic blood pressure \\\u003C140 mm Hg, diastolic blood pressure \\\u003C 90 mm Hg, and heart rate \\\u003C110 bpm at screening and at baseline for dosing session\n* Body mass index (BMI) in the range of 18 to 36 kg\u002Fm2\n* Cannabis use within the past three years but none in the month prior to the first test session\n* Negative urine test for illicit substance use and negative breath alcohol test (0% breath alcohol concentration) at screening and before study sessions\n\nExclusion Criteria\n\n* Use of psychoactive substances (aside from nicotine, caffeine, and alcohol) in the month prior to study initiation\n* Current use of over the counter (OTC) drugs, supplements\u002Fvitamins, or prescription medications that, in the opinion of the investigator or medical staff, will impact the participant's safety.\n* Current use of any prescription or non-prescription medications, including herbal medicines and supplements, that are known to interact with cannabis or pregnenolone\n* Self-report or ECG indicating clinically significant cardiovascular conditions, including coronary artery disease, stroke, angina, uncontrolled hypertension, arrhythmias (e.g. atrial fibrillation), heart valve placement, or TIA in the past year.\n* History of hormone-sensitive conditions, including but not limited to gynecologic cancers (breast, ovarian, uterine, etc), endometriosis, uterine fibroids, thyroid, pituitary and\u002For adrenal syndromes, polycystic ovarian syndrome, etc.\n* Epilepsy or a history of seizures\n* Any of the following laboratory values during screening or upon admission:\n\n  * AST \\> 165 U\u002FL (normal range 19-55)\n  * ALT \\> 216 U\u002FL (normal range 19-72)\n  * Alkaline phosphatase \\> 1.5x upper limit of normal (ULN)\n  * Total bilirubin \\>1.5 ULN\n  * Glomerular filtration rate (EGFR) \\\u003C 60 ml\u002Fmin\u002F1.73m2\n* Current or past history of meeting DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, or bipolar I or II disorder\n* Other unstable and\u002For compromising medical or psychiatric conditions based on clinical interview and\u002For MINI results that would interfere with participant safety as determined by study physician, including suicidal ideation and\u002For attempt, psychosis\n* Previous diagnosis and treatment for Cannabis Use Disorder\n* Urine drug screen (e.g. Healgen Scientific 14 Panel Rapid Drug Test) indicating the presence of substances including amphetamines, barbiturates, benzodiazepines, cocaine, opioids (including fentanyl), PCP, and THC at screening and prior to study sessions\n* Breathalyzer screen indicating presence of alcohol at screening and prior to study sessions\n* Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing\n* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control including oral contraceptives, progestin implant, transdermal birth control patch, intrauterine device (IUD) or vaginal ring. Women who report use of condoms or diaphragm must use a \"double-barrier\" method of contraception (i.e. diaphragm and condoms).\n* SBP \\>\u002F= 140, DBP \\>\u002F= 90, or pulse \\>\u002F=100 during screening and\u002For prior to dosing session\n* Has donated blood within 30 days of the study\n* Allergy to eggs or other food allergies that would make ingestion of brownie mix unsafe.\n* Use of concomitant medications, including herbal medicines and botanical supplements, that are strong inhibitors or inducers of CYP3A4 and CYP2C9","65 Years",{"count":132,"type":22},20,[134],"PHASE2","The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.",[27],[138,139,140,141,142,143],"cannabis","pregenolone","cannabis intoxication","THC","delta-9-thc","CB1 receptor","2026-04-27",{"date":146,"type":37},"2026-05-01",{"date":148,"type":37},"2026-04-24",{"date":150,"type":22},"2029-01-01",{"name":123,"class":44},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":58,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":45},"100629182","exploring-the-effect-of-cannabidiol-on-cannabis-tolerance-using-a-novel-vaporiser-device-in-heavy-users-stage-1-100629182","NCT07471347","Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1)","Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users: A Randomised Placebo-Controlled Experimental Study (Stage 1)","ENDURANCE","Inclusion Criteria:\n\n1. Adults, between 18 and 45 years old\n2. Heavy and frequent cannabis user: using 7-14 grams of high potency cannabis per week over the past month, and using cannabis on at least 5 days per week over the past month\n3. Positive urine drug screen (UDS) for cannabis\n4. Willing to abstain from cannabis use for 4 hours before any experimental session.\n5. Willing to eat two non-vegan full-fat yoghurts to aid drug absorption\n6. Providing written informed consent.\n\nExclusion Criteria:\n\n1. Dependent use of alcohol or illicit drugs (apart from cannabis or tobacco\u002Fnicotine)\n2. Not able to provide a UDS which is negative for illicit drugs (apart from cannabis)\n3. Not able to provide a negative alcohol breath test\n4. Personal or family history (first-degree) of psychosis or mania\n5. Currently prescribed antidepressant, mood-stabilising, antipsychotic or stimulant medication, or regular medication for a significant medical condition (e.g. antihypertensives, anticonvulsants, anticoagulants, or immunosuppressants)\n6. Diagnosis of a major medical or psychiatric illness that the study doctor considers inappropriate for the purposes of this study\n7. Female participants who are pregnant or mothers who are lactating\n8. Not willing to use an adequate form of contraception for the duration of the study\n9. Participant in another experimental medicine study or clinical trial within the past three months.","45 Years",{"count":162,"type":22},10,[60],"Cannabis contains delta-9-tetrahydrocannabinol (THC), which causes intoxication. People who use cannabis frequently often develop tolerance, meaning they need to use more THC to feel the same effects. Cannabidiol (CBD) is another compound found in cannabis that is not intoxicating and may influence how THC affects the body and brain.\n\nThis study will examine whether taking CBD changes how much THC heavy cannabis users consume to reach their usual level of intoxication. The study will also develop a new laboratory method that allows participants to safely and gradually self-administer THC using a vaporiser, similar to how cannabis is used in real-world settings.\n\nThe study will include around 30 adults who use cannabis heavily. In the first stage, participants will take part in pilot sessions to help refine the THC administration procedure. In the second stage, participants will attend two study sessions and receive a single oral dose of CBD or placebo, in a random order. After this, they will inhale THC using a vaporiser and decide when to stop based on how intoxicated they feel.\n\nResearchers will measure how much THC is used, along with mood, mental health symptoms, thinking abilities, physical measures such as heart rate and blood pressure, and blood levels of THC and CBD. The results will help improve understanding of cannabis tolerance and whether CBD alters responses to THC in heavy cannabis users.",[27],[87,141,167],"Delta-9-tetrahydrocannabinol","2026-03-12",{"date":170,"type":37},"2026-03-13",{"date":172,"type":22},"2026-03",{"date":174,"type":22},"2026-12",{"name":176,"class":44},"King's College London",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":103,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":58,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100538607","phase-1-vaporized-cannabis-administration-and-co-administration-of-alcohol-on-impairment-100538607","NCT06293040","Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment","The Impact of Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment","Inclusion Criteria:\n\n1. Have provided written informed consent\n2. Be at least 21 years of age\n3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests\n4. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit\n5. Have not donated blood in the prior 30 days\n6. Report at least 1 day of binge drinking in the past 3 months (greater than 4 or 5 drinks on a single occasion for women and men, respectively)\n7. Report at least 1 use of cannabis in the past 3 years\n8. Provide negative urine test for illicit drug use (excluding THC) and negative breath alcohol test (0% BAC) at screening and before study sessions\n9. Report at least 1 lifetime instance of simultaneous alcohol and cannabis use\n10. Current concomitant prescription medication use that may interact with the investigational study drug, including inhibitors and inducers of CYP2CP and CYP3A4 as well as highly-protein bound drugs and drugs with a narrow therapeutic index such as warfarin, cyclosporine, and amphotericin B\n\nExclusion Criteria:\n\n1. Psychoactive drug use (aside from cannabis, nicotine, alcohol, or caffeine) in the past month\n2. History of or current evidence of significant medical condition that would put the participant at risk\n3. Evidence of current psychiatric condition (MINI for DSM-V)\n4. Meet criteria for severe alcohol use disorder (MINI for DSM-V)\n5. CIWA-Ar score \\> 9\n6. Use of cannabis, on average, more than 3 days\u002Fweek over past 3 months\n7. Enrollment in another clinical trial or receiving of any drug as part of research within past 30 days\n8. Shipley vocabulary score \\\u003C18 (corresponds to 5th grade reading level)",{"count":185,"type":22},90,[109],"This human laboratory study will use cognitive, behavioral, and subjective measures to characterize impairment associated with co-use of alcohol and vaporized cannabis. Participants (n=32) will complete 7 double-blind, double-dummy outpatient sessions in randomized order. In each session, participants will self-administer placebo (0 mg THC) or active vaporized cannabis (5 or 25 mg THC, via a handheld vaporizer called the Mighty Medic) and a placebo drink (BAC 0.0%) or alcohol drink calculated to produce a breath alcohol concentration (BAC) of 0.05%. Participants will also complete a positive control session in which the participant administers placebo cannabis and alcohol at a target BAC of 0.08% (the legal threshold for driving impairment in most U.S. states).",[27,189],"Alcohol Intoxication","2025-09-10",{"date":192,"type":37},"2025-09-12",{"date":194,"type":37},"2024-09-26",{"date":196,"type":22},"2027-12",{"name":123,"class":44},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":103,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":58,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100590410","the-efficacy-of-a-smart-phone-based-test-on-measuring-pupillary-light-reflex-alterations-following-cannabis-use-healthy-in-adults-100590410","NCT06967051","The Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults","An Open Label Pilot Study Evaluating the Efficacy of a Smart Phone-based Test on Measuring Pupillary Light Reflex Alterations Following Cannabis Use Healthy in Adults","Inclusion Criteria:\n\n1. Males and females 21 years of age or older\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   2. Double-barrier method\n   3. Intrauterine devices\n   4. Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   5. Vasectomy of partner at least 6 months prior to screening\n   6. Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Self-reported cannabis users based on the Cannabis Use Questionnaire who are familiar and experienced with THC's acute psychoactive effects from the doses and route of administration to be used in this study without previous severe adverse reactions after cannabis ingestion\n4. Self-reported cannabis use at least 3x per month but no more than 3x per week\n5. Agrees to abstain from cannabis use for 3 days prior to study visit\n6. Willingness to complete all assessments associated with the study and agrees to safe transportation home\n7. Provided voluntary, written, informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption study products\n3. Current and ongoing neurological or ophthalmological issue that could affect the retina (blindness, glaucoma, dry eyes, retinal diseases, pupil abnormalities, cataracts, sensitivity to bright lights)\n4. History of surgery on eyes or retinas except for laser corneal surgery\n5. Current or history of psychological disorders (e.g., schizophrenia and psychosis)\n6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n7. Type I or Type II diabetes with diabetic retinopathy\n8. Unstable metabolic disease or chronic diseases as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (see below)\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an unstable autoimmune disease\n16. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n17. Alcohol or drug abuse within the last 12 months\n18. Impairment from illicit drugs or alcohol during their study visit, as assessed by the QI or Sub-Investigator\n19. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n20. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (see below)\n21. Participation in other research studies 30 days prior to baseline, as assessed by the QI\n22. Individuals who are cognitively impaired and\u002For who are unable to give informed consent\n23. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":132,"type":22},[60],"The goal of this open label study is to evaluate the efficacy of smart phone-based test (SOBEREYE OPTOVERA) on measuring pupillary light reflex (PLR) alterations following cannabis use healthy in adults. The main question it aims to answer is:\n\nCan SOBEREYE OPTOVERA detect PLR alterations following cannabis consumption in healthy adults, in comparison to a pupillometer?\n\nParticipants will be given two 5 mg capsules to be ingested for the 10 mg THC dose or five 5 mg capsules to be ingested for the 25 mg THC. Participants will be asked to complete PLR tests throughout the study day.",[27,209],"Drug Effects",[211,26,209,212,213,214],"Pupillometer","SOBEREYE","OPTOVERA","Pupillary Light Reflex","2025-07-14",{"date":217,"type":37},"2025-07-17",{"date":219,"type":37},"2025-05-22",{"date":221,"type":22},"2025-08",{"name":223,"class":224},"Sobereye Inc.","INDUSTRY",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":103,"sex":17,"minAge":18,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":58,"phases":235,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100428168","early-phase-1-thc--cbd-and-memory-study-100428168","NCT04855526","THC + CBD and Memory Study","Effects of Marijuana on Memory-Related Neurochemistry and Neural Response","Inclusion Criteria:\n\n* Right-handed\n* Prior MJ users (has used MJ at least once in the past year, but no more than 1x\u002Fmonth in the past 12 months)\n* Medically healthy (as determined by medical history and treatment)\n* Adequate comprehension of English in order to complete study materials\n* Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe)\n\nExclusion Criteria:\n\n* Participant currently uses psychoactive medications or substances\n* Psychiatric diagnoses (determined by DSM-V)\n* Participant heavily or regularly uses MJ (more than 1x\u002Fmonth in the past year)\n* Current or past substance dependence (including MJ)\n* Positive urine toxicology screens\n* Positive pregnancy screens\n* MRI contraindications (e.g., heart pacemaker)","40 Years",{"count":234,"type":22},9,[236],"EARLY_PHASE1","Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper\u002Fpencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.",[72,26,27],[240,241,242,141,138,243,244,245,246],"marijuana","cannabidiol","memory","intoxication","MRI","glutamate","MRS","2025-03-13",{"date":249,"type":37},"2025-03-17",{"date":251,"type":22},"2025-12-01",{"date":253,"type":22},"2026-12-30",{"name":255,"class":44},"Hartford Hospital"]